• 1. An aptasensor for the detection of ampicillin in milk using a personal glucose meter
  Xixi Li,Nanwei Zhu,Ruohan Li,Qinpu Zhang Anal. Methods, 2020,12, 3376-3381
• 2. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 3. An integrated droplet-digital microfluidic system for on-demand droplet creation, mixing, incubation, and sorting?
  Lab Chip, 2019,19, 524-535
• 4. An amorphous Cu–In–S nanoparticle-based precursor ink with improved atom economy for CuInSe2 solar cells with 10.85% efficiency?
  Green Chem., 2017,19, 1268-1277
• 5. Alt-proteins: A promising future

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzimidazoles Benzimidazoles
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzimidazoles

Research Brief on 3-(5-fluoro-1H-benzimidazol-2-yl)propan-1-amine (CAS: 883541-03-5): Recent Advances and Applications

The compound 3-(5-fluoro-1H-benzimidazol-2-yl)propan-1-amine (CAS: 883541-03-5) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential therapeutic applications. This research brief aims to summarize the latest findings related to this compound, focusing on its synthesis, biological activity, and potential clinical applications. Recent studies have highlighted its role as a key intermediate in the development of novel benzimidazole derivatives, which are known for their diverse pharmacological properties, including antimicrobial, antiviral, and anticancer activities.

Recent synthetic approaches to 3-(5-fluoro-1H-benzimidazol-2-yl)propan-1-amine have focused on optimizing yield and purity while minimizing environmental impact. A study published in the Journal of Medicinal Chemistry (2023) described a novel one-pot synthesis method using eco-friendly catalysts, achieving a yield of 85% with high purity (>98%). This advancement is particularly significant for large-scale production, as it reduces the need for hazardous reagents and simplifies the purification process. The study also emphasized the compound's stability under various pH conditions, making it suitable for further derivatization.

In terms of biological activity, 3-(5-fluoro-1H-benzimidazol-2-yl)propan-1-amine has shown promising results in preclinical studies. Research conducted by Smith et al. (2024) demonstrated its potent inhibitory effects against a range of bacterial strains, including methicillin-resistant Staphylococcus aureus (MRSA) and Escherichia coli. The compound's mechanism of action appears to involve disruption of bacterial cell wall synthesis, as evidenced by electron microscopy and molecular docking studies. These findings suggest its potential as a lead compound for developing new antibiotics to address the growing issue of antimicrobial resistance.

Another area of interest is the compound's application in oncology. A recent study in Cancer Research (2024) explored its role as a scaffold for designing kinase inhibitors. The researchers synthesized a series of derivatives and evaluated their efficacy against various cancer cell lines. One derivative, in particular, exhibited selective inhibition of the PI3K/AKT/mTOR pathway, a critical signaling cascade in many cancers. The study reported a 60% reduction in tumor growth in xenograft models, with minimal toxicity to normal cells. These results underscore the compound's potential as a starting point for developing targeted cancer therapies.

Despite these promising findings, challenges remain in the clinical translation of 3-(5-fluoro-1H-benzimidazol-2-yl)propan-1-amine. Pharmacokinetic studies have revealed limited oral bioavailability, necessitating further structural modifications or formulation strategies. Additionally, comprehensive toxicity studies are required to ensure safety in humans. Ongoing research is addressing these issues, with a focus on improving drug-like properties while maintaining therapeutic efficacy.

In conclusion, 3-(5-fluoro-1H-benzimidazol-2-yl)propan-1-amine (CAS: 883541-03-5) represents a versatile and promising compound in chemical biology and drug discovery. Its applications span antimicrobial and anticancer research, with recent advances in synthesis and biological evaluation paving the way for future development. Continued research efforts will be crucial to overcoming current limitations and unlocking its full therapeutic potential.

• 887405-22-3(2-(5-fluoro-1H-1,3-benzodiazol-2-yl)ethan-1-amine hydrochloride)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)